Clinical Study on the Prevention of Driver Gene Negative Ib-IIIb Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors

NCT05834413 · tracked via the Priya Life Science China tracker

Sponsor

Shanghai University of Traditional Chinese Medicine

Phase

Not applicable

Started

2023-05-01

Last updated

2026-05-13

Condition(s) studied

Lung Cancer

Investigational drug(s) / intervention(s)

chemotherapy plus TCM 1&ICIs plusTCM2chemotherapy plus TCM 1placebo &ICIs plus TCM2 placebo

chemotherapy plus TCM 1&ICIs plusTCM2: In China,TCM herbs are given on the basis of the TCM syndrome differentiation as diagnosed by the TCM herbal specialist. Prescriptions formulated into granules origin from Professor Liu Jia-xiang and Xu Ling. Package of granules is made into two types with functions such as tonifying the stomach and nourishing the blood recipe, benefiting Qi Yin and detoxification and resolving masses recipe. The herbal treatment is adapted to the syndromes. Chemotherapy：Vincristine/paclitaxel/docetaxel/pemetrexed/gemcitabine plus cisplatin/carboplatin：administrated for patients with NSCLC requiring post-operative adjuvant therapy. ICIs：Nivolumab/Pembrolizumab/Durvalumab/Atezolizumab/ Camrelizumab/Dupilumab/Sintilimab/Tislelizumab：administrated for patients with NSCLC requiring post-operative adjuvant therapy.

chemotherapy plus TCM 1placebo &ICIs plus TCM2 placebo: Chemotherapy：Vincristine/paclitaxel/docetaxel/pemetrexed/gemcitabine plus cisplatin/carboplatin：administrated for patients with NSCLC requiring post-operative adjuvant therapy. ICIs：Nivolumab/Pembrolizumab/Durvalumab/Atezolizumab/ Camrelizumab/Dupilumab/Sintilimab/Tislelizumab：administrated for patients with NSCLC requiring post-operative adjuvant therapy.

Study summary

This project adopts a prospective, multicenter, randomized controlled clinical study to investigate the treatment of TCM in postoperative patients with driver gene negative lung cancer, according to two phases of postoperative adjuvant therapy: (i) chemotherapy phase immunotherapy phase. In this study, 367 patients (183 in the control group and 184 in the trial group) will be observed over 4 years, and the quality of life, toxic effects and safety of this therapy will be investigated. This study will provide evidence-based evidence for the establishment and optimization of a new model of postoperative staged TCM with adjuvant chemo-immunotherapy for lung cancer.

Eligibility

Sex

ALL

Min age

18 Years

Max age

74 Years

Healthy volunteers

Inclusion Criteria: 1. Patients who underwent complete surgical resection (R0) with postoperative pathology confirmed as stage Ib to IIIb non-small cell lung cancer. 2. Patients whose tissue or blood specimens tested negative for driver genes. 3. Patients who received their first chemotherapy within 8 weeks postoperatively. 4. Age ≥ 18 years ≤ 74 years, regardless of gender. 5. Eastern Cooperative Oncology Group performance status (ECOG PS) ≤ 2 points. 6. absolute neutrophil value \>1.5×109 /L, platelet count \>80×109 /L, hemoglobin \>90mg/dL; no abnormal liver and kidney function test results. 7. Understand and agree to participate in this study and sign the informed consent form. Exclusion Criteria: 1. Having unresectable or metastatic disease, pathology reports without a clear pathological diagnosis, showing the presence of residual lesions at the microscopic surgical margins, and surgical residual lesions. 2. Any medical condition with a life expectancy of less than 5 years, except for risk of recurrent lung cancer. 3. Current malignant disease or history of malignant disease (except resected NSCLC), combined with serious diseases of the heart, liver, kidney and hematopoietic system, diagnosed and/or requiring treatment within the past three years. 4. With a history of psychiatric disorders that are not easily controlled. 5. Patients who are pregnant or lactating. 6. Patients who are allergic to therapeutic drugs.

Primary outcome measure(s)

Disease-free Survival(DFS) — 5 years
Time from patient enrollment to date of objective tumour recurrence from any cause.

Trial sites (1)

Facility	City	Region	Status
YueYang Hosptial of Intergrated Traditional Chinese and Western Medicine,Shanghai University of Traditional Chinese Medicine	Shanghai	Shanghai Municipality	Recruiting

More Shanghai University of Traditional Chinese Medicine trials in China

Multicenter Cohort Study on Osteoporosis Recruiting

TCM Daoyin Therapy in Individuals At-risk for COPD Active, not recruiting

EOCRCPred: an AI Model to Predict Survival in EOCRC Patients After Surgery Starting soon

The Association of Transgelin-2, Metallothionein-2 and Ezrin With Asthma Recruiting

Baduanjin Training for Depression and Anxiety Patients Recruiting

Other trials for the same condition

TROP2 NMR Concordance Study Recruiting

Real-World Outcomes of Resected EGFR-Mutated NSCLC Patients Treated With Adjuvant EGFR-TKI in China Recruiting

Efficacy and Safety of Intratumoral Toluenesulfonamide (PTS) Injection in Stage IV Driver Gene-Negative NSCLC With/Without Chemoimmunotherapy Recruiting

Symptoms Burden in Lung Cancer Patients Undergoing Definitive Chemoradiotherapy: Insights From Electronic Patient-Reported Outcomes Recruiting

Development and Demonstration of Intelligent Assessment Based on Multi-modal Information Fusion for Tumor Risk and Diagnosis and Treatment Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05834413 on ClinicalTrials.gov ↗ ← All trials in China